Pharmaceutical spend continues to be a main cost driver in the health care system, while additional governmental regulations challenge payers and providers. Despite factors in the marketplace that are out of our control, we are proud to have delivered a single-digit drug trend rate to our clients in 2015, based on total cost.
Learn more about all of the efforts Navitus has in place today to counter drug trend.
Hospira, Inc., a Pfizer company, recalled 8.4% Sodium Bicarbonate Injection USP. These products came from lot 56-148-EV, expiring August 1, 2017.
Teva Pharmaceuticals voluntarily recalled amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL) vials from lot 4750915. This drug is used in the short term to treat severe infections.
Contact Us | Careers | MedicareRx (PDP) | Navi-Gate Rx | Site Map | Confidentiality Statement | Vendor/FDR
Download Adobe Reader